Related Experiment Video

Updated: Aug 5, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Increased platelet aggregation and release reaction in myotonic dystrophy

N M Bornstein1, M Zahavi, A D Korczyn

  • 1Department of Neurology, Tel Aviv University, Ramat Aviv, Israel.

Journal of the Neurological Sciences
|April 1, 1988
PubMed

Insights

Patients with myotonic dystrophy (MyD) show heightened platelet aggregation (PA) and release reactions. This suggests platelet dysfunction, potentially linked to alpha 2-receptor and calcium channel abnormalities in MyD.

Area of Science:

  • Hematology
  • Neurology
  • Medical Research

Background:

  • Myotonic dystrophy (MyD) is a multisystem disorder.
  • Platelet function abnormalities may contribute to MyD pathophysiology.
  • Understanding platelet behavior in MyD is crucial for comprehensive patient care.

Purpose of the Study:

  • To investigate platelet aggregation (PA) and release reactions in patients with myotonic dystrophy (MyD).
  • To compare platelet function markers between MyD patients and healthy controls.
  • To explore potential mechanisms underlying platelet abnormalities in MyD.

Main Methods:

  • Studied PA induced by (-)-epinephrine and adenosine diphosphate (ADP) in 16 MyD patients and 14 controls.
  • Measured plasma beta-thromboglobulin (beta-TG) levels as a marker of in vivo platelet activation.
  • Assessed in vitro 5-[14C]hydroxytryptamine (5-HT) release from platelets.

Main Results:

  • MyD patients exhibited significantly higher PA induced by (-)-epinephrine and ADP compared to controls.
  • Elevated plasma beta-TG levels were observed in MyD patients, indicating increased in vivo platelet release.
  • Increased ADP- and epinephrine-induced platelet 5-HT release was noted in MyD patients.

Conclusions:

  • Platelets in MyD patients display enhanced aggregation and release reactions.
  • Findings suggest abnormalities in alpha 2-receptor function and platelet release mechanisms in MyD.
  • Potential alterations in platelet membrane calcium (Ca2+) fluxes may be involved in MyD-related platelet dysfunction.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Related Concept Videos

Muscle Contraction01:15

Muscle Contraction

Muscle Contraction01:10

Muscle Contraction

In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive muscle...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...